It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Poor bioavailability due to the inability to cross the cell membrane is one of the major reasons for the failure of a drug in clinical trials. We have used molecular dynamics simulations to predict the membrane permeability of natural drugs—withanolides (withaferin-A and withanone) that have similar structures but remarkably differ in their cytotoxicity. We found that whereas withaferin-A, could proficiently transverse through the model membrane, withanone showed weak permeability. The free energy profiles for the interaction of withanolides with the model bilayer membrane revealed that whereas the polar head group of the membrane caused high resistance for the passage of withanone, the interior of the membrane behaves similarly for both withanolides. The solvation analysis further revealed that the high solvation of terminal O5 oxygen of withaferin-A was the major driving force for its high permeability; it interacted with the phosphate group of the membrane that led to its smooth passage across the bilayer. The computational predictions were tested by raising and recruiting unique antibodies that react to withaferin-A and withanone. The time-lapsed analyses of control and treated cells demonstrated higher permeation of withaferin-A as compared to withanone. The concurrence between the computation and experimental results thus re-emphasised the use of computational methods for predicting permeability and hence bioavailability of natural drug compounds in the drug development process.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Institute of Advanced Industrial Science and Technology (AIST), AIST-INDIA DAILAB, DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Tsukuba, Japan (GRID:grid.208504.b) (ISNI:0000 0001 2230 7538)
2 Indian Institute of Technology (IIT) Delhi, DAILAB, Department of Biochemical Engineering and Biotechnology, New Delhi, India (GRID:grid.417967.a) (ISNI:0000 0004 0558 8755)
3 National Institute of Advanced Industrial Science and Technology (AIST), AIST-INDIA DAILAB, DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Tsukuba, Japan (GRID:grid.208504.b) (ISNI:0000 0001 2230 7538); Hanyang University, Department of Bioengineering, College of Engineering, Seoul, Republic of Korea (GRID:grid.49606.3d) (ISNI:0000 0001 1364 9317)
4 National Institute of Advanced Industrial Science and Technology (AIST), AIST-INDIA DAILAB, DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Tsukuba, Japan (GRID:grid.208504.b) (ISNI:0000 0001 2230 7538); Hanyang University, Department of Bioengineering, College of Engineering, Seoul, Republic of Korea (GRID:grid.49606.3d) (ISNI:0000 0001 1364 9317); GeneMedicine Co., Ltd, Seoul, Republic of Korea (GRID:grid.49606.3d)
5 Hanyang University, Department of Bioengineering, College of Engineering, Seoul, Republic of Korea (GRID:grid.49606.3d) (ISNI:0000 0001 1364 9317); GeneMedicine Co., Ltd, Seoul, Republic of Korea (GRID:grid.49606.3d); Institute of Nano Science and Technology (INST), Seoul, Republic of Korea (GRID:grid.49606.3d)




